Last updated: February 19, 2026
This report analyzes European Patent EP3297605, focusing on its granted claims, exemplified embodiments, and the surrounding patent landscape. The patent claims a specific pharmaceutical composition and its use in treating certain medical conditions. Understanding the breadth of these claims and the competitive patent environment is critical for R&D strategy and investment decisions.
What is the Core Invention Claimed in EP3297605?
European Patent EP3297605, titled "Pharmaceutical composition comprising tacrolimus for the treatment of skin diseases," claims a pharmaceutical composition containing tacrolimus and a specific set of excipients. The primary objective is the topical treatment of inflammatory skin conditions.
Claim 1 of EP3297605 reads as follows:
"A pharmaceutical composition for topical administration, comprising:
(a) tacrolimus; and
(b) an oily phase comprising at least one oleaginous ester, at least one fatty alcohol, and at least one non-ionic emulsifier, wherein the oily phase has a globule size distribution wherein the D90 is less than or equal to 500 nm." [1]
This claim defines the invention based on three key elements: the active pharmaceutical ingredient (tacrolimus), the composition of the oily phase (specific excipients), and a critical physical characteristic of the oily phase (globule size distribution).
What Specific Excipients are Defined?
The patent details specific categories of excipients that constitute the oily phase. These are crucial for defining the scope of the claimed composition.
- Oleaginous Ester: The patent indicates that the oleaginous ester can be a mono-, di-, or triglyceride of fatty acids, or an ester of a fatty acid with a monovalent or polyvalent alcohol. Examples provided include isopropyl myristate, decyl oleate, and glyceryl monostearate. [1]
- Fatty Alcohol: Suitable fatty alcohols are described as linear or branched, saturated or unsaturated, and having from 8 to 22 carbon atoms. Specific examples include lauryl alcohol, cetyl alcohol, and stearyl alcohol. [1]
- Non-ionic Emulsifier: The patent specifies non-ionic emulsifiers that are polyoxyethylene ethers of fatty alcohols, polyoxyethylene sorbitan fatty acid esters, or polyoxyethylene fatty acid esters. Examples include polysorbate 80 and polyethylene glycol stearate. [1]
The combination of these excipients and their specific function within the oily phase, alongside the defined globule size, forms the core of the inventive concept.
What are the Key Technical Features and Advantages?
The patent emphasizes specific technical features of the composition, linking them to therapeutic advantages. The primary focus is on enhancing the delivery and efficacy of tacrolimus.
What is the Significance of the Oily Phase Globule Size?
The defined globule size distribution of the oily phase, specifically that the D90 is less than or equal to 500 nm, is a critical parameter.
- D90: This metric represents the diameter below which 90% of the oily globules are found. A smaller D90 indicates a more uniform and finer dispersion of the oily phase within the composition. [1]
- Mechanism: The patent suggests that this fine dispersion facilitates improved penetration of tacrolimus into the skin layers where it exerts its therapeutic effect. This can lead to enhanced efficacy and potentially reduced systemic exposure. [1]
What Therapeutic Indications are Targeted?
The patent explicitly targets the treatment of inflammatory skin diseases. While specific conditions are not exhaustively listed in the core claims, the description and examples point to a broad application.
- Primary Indications: The patent's title and description focus on "skin diseases." [1]
- Exemplified Conditions: The provided examples and background information suggest applications in conditions such as atopic dermatitis, psoriasis, and other inflammatory dermatoses responsive to immunosuppressants. [1]
The invention aims to provide a more effective and potentially better-tolerated topical formulation of tacrolimus for these conditions.
What is the Patent's Geographic Coverage and Term?
European Patent EP3297605 is a granted European patent, meaning it is validated in designated member states of the European Patent Organisation.
- Designated States: The patent is in force in various European countries. The specific list of designated states can be found in the European Patent Register. As of its grant date, it was validated in states including Germany, France, the United Kingdom, and Italy, among others. [1]
- Grant Date: The patent was granted on January 31, 2019. [1]
- Expiry Date: The patent has a term of 20 years from its filing date. The filing date was October 25, 2016. Therefore, the patent is expected to expire on October 25, 2036, in all designated states where it is maintained. [1]
The term of the patent provides a period of market exclusivity for the claimed composition and its use.
What is the Competitive Patent Landscape for Topical Tacrolimus?
The landscape for topical tacrolimus is characterized by multiple patents covering various formulations, delivery systems, and therapeutic uses. EP3297605 is one among several. Key competitors often hold patents related to:
- Specific Formulations: Patents may claim unique combinations of excipients, emulsifiers, and stabilizers designed to improve tacrolimus solubility, stability, skin penetration, or reduce irritation.
- Delivery Systems: Encapsulation technologies (e.g., liposomes, nanoparticles) or specialized vehicles for enhancing topical drug delivery are also patented.
- Methods of Treatment: Patents can cover specific dosages, treatment regimens, or the use of tacrolimus for particular dermatological conditions not broadly covered by earlier patents.
- Polymorphs and Salts: Novel crystalline forms or salt forms of tacrolimus with improved properties may be subject to patent protection.
Companies actively developing or marketing topical tacrolimus products typically have a portfolio of patents designed to protect their innovations and create a barrier to entry. Generic manufacturers often seek to invalidate existing patents or develop non-infringing formulations.
Example of Comparative Patent Scope:
| Patent Identifier |
Core Claim Focus |
Key Differentiating Feature |
| EP3297605 |
Pharmaceutical composition with tacrolimus and a specific oily phase composition |
D90 globule size $\leq$ 500 nm of the oily phase |
| Example Competitor Patent A |
Topical formulation of tacrolimus |
Claims a specific surfactant system and ointment base for reduced stinging |
| Example Competitor Patent B |
Method of treating atopic dermatitis with tacrolimus |
Claims a specific dosing frequency and application area for severe atopic dermatitis |
This comparison highlights how different patents can claim overlapping technologies but with distinct inventive steps based on specific formulation components or therapeutic applications.
What are the Potential Implications for Market Entry and R&D?
The patent protection afforded by EP3297605 has direct implications for companies seeking to develop or market similar topical tacrolimus products.
For Developers of New Formulations:
- Freedom-to-Operate (FTO) Analysis: Companies must conduct thorough FTO analyses to ensure their proposed formulations do not infringe EP3297605 or other relevant patents. This involves comparing the composition and manufacturing process of the intended product against the claims of EP3297605.
- Non-Infringing Alternatives: If a proposed formulation falls within the scope of EP3297605, developers may need to modify their composition, manufacturing process, or target indication to avoid infringement. This could involve using different excipients, achieving a larger globule size distribution, or targeting conditions not explicitly covered by the patent's descriptive text, provided it doesn't implicitly infringe.
- Licensing: In some cases, obtaining a license from the patent holder may be an option to gain the right to commercialize a product that infringes.
For Generic Manufacturers:
- Patent Expiry: Generic manufacturers will target market entry upon the expiry of EP3297605 and any other relevant patents.
- Patent Challenges: Generic companies may attempt to invalidate EP3297605 through opposition or revocation proceedings, arguing lack of novelty, inventive step, or insufficient disclosure.
- Formulation Design-Around: Generic companies will aim to develop formulations that are therapeutically equivalent but do not infringe the patent claims, often by altering excipient combinations or manufacturing methods while maintaining bioequivalence.
For Investors:
- Market Exclusivity: The patent's remaining term provides market exclusivity for the patent holder, influencing revenue projections and competitive dynamics.
- Pipeline Strength: The existence of such patents can indicate the strength of a company's R&D pipeline and its commitment to protecting intellectual property in key therapeutic areas.
- Litigation Risk: The potential for patent litigation between innovators and generic companies is a significant factor in assessing investment risk and opportunity.
Key Takeaways
- EP3297605 protects a topical pharmaceutical composition containing tacrolimus with a specific oily phase characterized by a D90 globule size of $\leq$ 500 nm.
- The patent covers a particular combination of oleaginous esters, fatty alcohols, and non-ionic emulsifiers designed for topical application to treat inflammatory skin diseases.
- The patent is valid until October 25, 2036, providing market exclusivity in designated European states.
- The competitive landscape for topical tacrolimus includes numerous patents covering formulations, delivery systems, and methods of treatment, necessitating thorough freedom-to-operate analyses.
FAQs
-
What specific inflammatory skin diseases does EP3297605 claim to treat?
The patent title and description focus on "skin diseases" generally. While specific examples like atopic dermatitis and psoriasis are implied through background information and patent prosecution, the core claims are broadly drafted for inflammatory skin diseases treatable with tacrolimus.
-
Can a generic formulation with a D90 greater than 500 nm avoid infringing EP3297605?
Yes, if the oily phase globule size distribution's D90 is greater than 500 nm, the formulation would fall outside the scope of Claim 1 of EP3297605, assuming all other elements of the claim are also not met.
-
What happens if EP3297605 is successfully challenged and revoked?
If the patent is revoked, the invention it covers would enter the public domain. This could lead to increased competition, including the earlier market entry of generic products, and reduce the exclusivity period for the patent holder.
-
Does EP3297605 cover the use of tacrolimus itself, or only the specific composition?
EP3297605 primarily claims a specific "pharmaceutical composition" and its use. It does not broadly claim the use of tacrolimus for all skin diseases, but rather the use of the claimed composition for treating them.
-
What are the implications of the D90 parameter for tacrolimus skin penetration?
The patent suggests that the smaller D90 value ( $\leq$ 500 nm) leads to improved penetration of tacrolimus into the skin. This is considered a key technical advantage driving enhanced efficacy and potentially reduced side effects due to better localized delivery.
Citations
[1] European Patent EP3297605 B1. (2019). Pharmaceutical composition comprising tacrolimus for the treatment of skin diseases. European Patent Office.
